Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation

Anesthesia and Analgesia

Volumn 82, Issue 1, 1996, Pages 167-172

  Tateishi, T ^a   Krivoruk, Y ^a   Ueng, Y F ^a   Wood, A J J ^a   Guengerich, F P ^a   Wood, M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; FENTANYL; SUFENTANIL;

ARTICLE; DEALKYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN TISSUE; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL;

ANALGESICS, OPIOID; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; ENZYME INHIBITORS; ERYTHROMYCIN; FENTANYL; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NORPREGNENES; RABBITS; SUFENTANIL; TROLEANDOMYCIN;

EID: 0030041685     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199601000-00031     Document Type: Article

References (37)

1. Guengerich EP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-407.
2. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease state using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
3. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12:1-51.
4. Bertilsson L, Henthron TK, Sanz E, et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
5. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquinsparteine polymorphism. Clin Pharmacol Ther 1991;50:233-8.
6. Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993;79:795-807.
7. Thummel KE, Kharasch ED, Podoll T, Kunze K. Human liver microsomal enflurane defluorination catalyzed by cytochrome. Drug Metab Dispos 1993;21:350-7.
8. Meuldermans W, Peer AV, Hendrickx J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988;69:527-34.
9. Silverstein JH, Rieders MF, McMullin M, et al. An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth Analg 1993;76:618-21.
10. Meuldermans W, Hendrickx J, Lauwers W, et al. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Dispos 1987;5:905-13.
11. Lavrijsen K, Van Houdt J, Van Dyck D, et al. Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans. Drug Metab Dispos 1990;18:704-10.
12. Yun C-H, Wood M, Wood AJJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. Anesthesiology 1992;77:467-74.
13. Guengerich FP, Martin MV, Beaune PH, et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051-60.
14. Wandel C, Bocker R, Bohrer H, et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 1994;73:658-61.
15. Watkins PB, Murray SA, Winkelman LG, et al. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P450: studies in rats and patients. J Clin Invest 1989;83:688-97.
16. Bartkowski RR, Goldberg ME, Larijani GE, Boerner T. Inhibition of alfentanil metabolism by erythromycin. Clin Pharmacol Ther 1989;46:99-102.
17. Bartkowski RR, Goldberg ME, Huffnagle S, Epstein RH. Sufentanil disposition. Anesthesiology 1993;78:260-5.
18. Roy SD, Hawes EM, Hubbard JW, et al. Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism [letter]. Lancet 1984;2:1393.
19. Kupfer A, Schmid B, Preising R, Pfaff G. Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism. Lancet 1984;2:517-8.
20. Kupfer A, Schmid B, Pfaff G. Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 1986;16:421-33.
21. Wang PP, Beaune P, Kaminsky LS, et al. Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. Biochemistry 1983;22:5375-83.
22. Gillam EMJ, Baba T, Kim B-R, et al. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification reconstitution of the enzyme. Arch Biochem Biophys 1993;305:123-31.
23. Sandhu P, Guo Z, Baba T, et al. Expression of modified human cytochrome P450 1A2 in Escherichia coli: stabilization, purification spectral characterization, and catalytic activities of the enzyme. Arch Biochem Biophys 1994;309:168-77.
24. Sandhu P, Baba T, Guengerich FP. Expression of modified human cytochrome P450 2C10 (2C9) in Escherichia coli: purification and reconstitution of catalytic activity. Arch Biochem Biophys 1993;306:443-50.
25. Gillam EMJ, Guo Z, Guengerich FP. Expression of modified human cytochrome P450 2E1 in Escherichia coli, purification, and spectral and catalytic properties. Arch Biochem Biophys 1994;312:59-66.
26. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-8.
27. Tateishi T, Wood AJJ, Guengerich FP, Wood M. Biotransformation of fentanyl in human liver microsomes. Biochem Pharmacol 1995. In press.
28. Matire PO, Vozeh S, Heykants J, et al. Population pharmacokinetics of alfentanil: the average dose-plasma concentration relationship and interindividual variability in patients. Anesthesiology 1987;66:3-12.
29. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
30. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
31. Monk JP, Beresford R, Ward A. Sufentanil; a review of its pharmacological properties and therapeutic use. Drugs 1988;36:286-313.
32. Stanski DR, Hug CC. Alfentanil - a kinetically predictable narcotic analgesic. Anesthesiology 1992;57:435-43.
33. Wang RW, Kari PH, Lu AYH, et al. Biotransformation of lovastatin. IV. Identification of cytochrome P-450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
34. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
35. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med 1988;109:682-3.
36. Watkins PB, Hamilton TA, Annesley TM, et al. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
37. Imaoka S, Enomoto K, Oda Y, et al. Lidocaine metabolism by human cytochrome P450s purified from hepatic microsomes: comparison with rat hepatic cytochrome P450s. J Pharmacol Exp Ther 1990;255:1385-91.